Jason has made over 1 trades of the Ovid Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 17,344 units of OVID stock worth $37,290 on 12 September 2022.
The largest trade he's ever made was selling 17,344 units of Ovid Therapeutics Inc stock on 12 September 2022 worth over $37,290. On average, Jason trades about 1,445 units every 0 days since 2019.
You can see the complete history of Mr. Tardio stock trades at the bottom of the page.
Jason Tardio serves as Chief Commercial Officer of the Company. Prior to joining Ovid, Mr. Tardio served as Vice President and Head of the Multiple Sclerosis franchise at Novartis. There, he was responsible for developing and managing all aspects of the U.S. commercial plan, brand P&L, strategy development, go-to-market modeling and day-to-day execution for Gilenya and Mayzent. Prior to Novartis, Mr. Tardio held roles of increasing responsibility at Biogen where most recently he served as GM, Managing Director for Biogen's Latin America South affiliate, leading the business for Argentina, Chile and Uruguay. Earlier at Biogen, Jason held a wide range of sales and marketing roles of increasing responsibility, including positions in Global Commercial Strategy, the U.S. Business Unit and at the international affiliate level. His more than 17 years of commercial experience in the biopharmaceutical industry began at Wyeth and Sepracor, with roles in sales, sales training and marketing. Jason holds a Bachelor of Science from The College of New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph's University.
Jason Tardio is 43, he's been the Chief Commercial Officer of Ovid Therapeutics Inc since 2019. There are 16 older and no younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
Jason's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.
Over the last 8 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan und Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include: